Both companies have received a request for additional information and documentary material from the U.S. Federal Trade Commission, Roche said, according to CNBC.
The expiration date of Roche's offer has been extended from 5 p.m. Friday, June 14 to 5 p.m. July 31, which suggests Spark shareholders now have until July 31 to tender their shares.
It's the fourth time the consummation of the deal has been delayed, with Roche withdrawing its pre-merger notification and report form first on March 18, the second time April 26 and a third time May 14.
Roche announced in late February a deal to buy the U.S. biotech for $4.8 billion, or $114.50 per share in cash.
Roche also said the U.K. Competition and Markets Authority has opened an investigation to obtain further information on the proposed deal to determine if the deal reduces competition in the U.K., warranting a Phase 2 review.
Why It's Important
Roche has a lot riding on the Spark deal given the pharma giant's recent focus on gene therapies.
Spark already has an approved gene therapy, Luxturna, for inherited retinal disease, and more investigational therapies in the pipeline for hemophilia A, hemophilia B, lysosomal storage disorders and neurodegenerative diseases.
The deal was originally expected to close in the second quarter of 2019. The most recent delay has made it impossible for the companies to meet the original scheduled completion date.
Roche and Spark said they remain committed to the transaction and are working cooperatively and expeditiously with the FTC.
Roche over-the-counter shares were trading up slightly at $34.26 at the time of publication Monday, while Spark shares were down 7.36 percent at $101.30.
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Sanofi's Leadership Transition: What You Need To Know
See more from Benzinga
- The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer
- The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
- Ideaya Biosciences IPO: What You Need To Know
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.